Inclusion Criteria:  For Multiple Myeloma cohort  Patients must have received at least 2 prior therapies;  Measurable levels of myeloma paraprotein  M-protein in serum >5 g/L; M-protein in urine >200mg/24h; Light chain Multiple Myeloma without measurable disease in the serum or urine: serum immunoglobulin free light chain ≥ 100 mg/L and abnormal serum immunoglobulin kappa lambda free light chain ratio.  For Indolent B-NHL  Progressed after standard treatment or no standard treatment with an established survival benefit is available; Imaging in screening showing at least one measurable lesion; In patients with CLL/SLL, circulating lymphocytes >= 5.0 × 10^9/L or lesions greater than 1.5 cm. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2; Life expectancy >=3 months; Adequate organ/system function; Female patients of childbearing age should agree to use contraceptive measures during the study period and for at least 6 months after study is stopped; male patients should agree to use contraception during the study period and for at least 6 months after study is stopped;  Exclusion Criteria:  Patients received allogenic haemopoietic stem cell transplantation, or autologous stem cell transplantation within 3 months; Diagnosed and/or treated additional malignancy within 3 years before the first dose; With factors affecting oral medication; Toxicity that is >=Grade 2 caused by previous cancer therapy; Patients with congenital bleeding or coagulopathy, or are being treated with anticoagulants; Patients with uncontrolled infections; Has received surgery, chemotherapy, radiotherapy or other anticancer therapies 2 weeks before the first dose; Has received Chinese patent medicines with anti-tumor indications that National Medical Products Administration(NMPA) approved within 2 weeks before the first dose; Pleural effusion, pericardial effusion or ascites that cannot be controlled and need repeated drainage; Central nervous system metastases; Has participated in other clinical studies within 4 weeks before the first dose; According to the judgement of the researchers, there are other factors that subjects are not suitable for the study.